Acrobiosystems Co.,Ltd.

SZSE:301080 Stock Report

Market Cap: CN¥5.1b

AcrobiosystemsLtd Valuation

Is 301080 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 301080 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 301080 (CN¥42.77) is trading below our estimate of fair value (CN¥59.44)

Significantly Below Fair Value: 301080 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 301080?

Key metric: As 301080 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 301080. This is calculated by dividing 301080's market cap by their current earnings.
What is 301080's PE Ratio?
PE Ratio47x
EarningsCN¥108.93m
Market CapCN¥5.12b

Price to Earnings Ratio vs Peers

How does 301080's PE Ratio compare to its peers?

The above table shows the PE ratio for 301080 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average49.5x
002880 Shenzhen Weiguang Biological Products
25x13.8%CN¥6.3b
688687 Beijing Kawin Technology Share-Holding
32.3x28.6%CN¥4.3b
300841 Chengdu Kanghua Biological Products
13.1x18.0%CN¥7.1b
688293 Shanghai OPM Biosciences
127.7x60.0%CN¥4.9b
301080 AcrobiosystemsLtd
47x29.9%CN¥5.1b

Price-To-Earnings vs Peers: 301080 is good value based on its Price-To-Earnings Ratio (47x) compared to the peer average (49.5x).

Price to Earnings Ratio vs Industry

How does 301080's PE Ratio compare vs other companies in the CN Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
301080 47.0xIndustry Avg. 35.5xNo. of Companies6PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 301080 is expensive based on its Price-To-Earnings Ratio (47x) compared to the CN Biotechs industry average (37.3x).

Price to Earnings Ratio vs Fair Ratio

What is 301080's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

301080 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio47x
Fair PE Ratio28.5x

Price-To-Earnings vs Fair Ratio: 301080 is expensive based on its Price-To-Earnings Ratio (47x) compared to the estimated Fair Price-To-Earnings Ratio (28.5x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 301080 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥42.77
CN¥47.91
+12.0%
4.5%CN¥50.00CN¥44.42n/a4
Nov ’25CN¥39.60
CN¥45.66
+15.3%
7.1%CN¥49.23CN¥41.00n/a4
Oct ’25CN¥42.30
CN¥46.93
+10.9%
10.5%CN¥54.30CN¥41.00n/a4
Sep ’25CN¥33.32
CN¥56.68
+70.1%
24.6%CN¥80.00CN¥44.42n/a4
Aug ’25CN¥35.42
CN¥56.78
+60.3%
24.5%CN¥80.00CN¥44.42n/a4
Jul ’25CN¥35.18
CN¥56.78
+61.4%
24.5%CN¥80.00CN¥44.42n/a4
Jun ’25CN¥39.18
CN¥56.78
+44.9%
24.5%CN¥80.00CN¥44.42n/a4
May ’25CN¥38.63
CN¥51.34
+32.9%
6.5%CN¥54.68CN¥48.00n/a2
Apr ’25CN¥41.82
CN¥80.59
+92.7%
5.3%CN¥87.70CN¥76.77n/a4
Mar ’25CN¥44.50
CN¥80.59
+81.1%
5.3%CN¥87.70CN¥76.77n/a4
Feb ’25CN¥39.92
CN¥80.59
+101.9%
5.3%CN¥87.70CN¥76.77n/a4
Jan ’25CN¥58.94
CN¥80.59
+36.7%
5.3%CN¥87.70CN¥76.77n/a4
Dec ’24CN¥66.80
CN¥80.59
+20.6%
5.3%CN¥87.70CN¥76.77n/a4
Nov ’24CN¥64.74
CN¥79.72
+23.1%
5.3%CN¥87.70CN¥76.27CN¥39.605
Oct ’24CN¥70.19
CN¥78.70
+12.1%
6.4%CN¥87.70CN¥72.75CN¥42.305
Sep ’24CN¥63.19
CN¥77.23
+22.2%
5.3%CN¥82.67CN¥72.75CN¥33.323
Aug ’24CN¥67.81
CN¥79.37
+17.1%
3.3%CN¥82.67CN¥76.27CN¥35.423
Jul ’24CN¥62.82
CN¥79.37
+26.4%
3.3%CN¥82.67CN¥76.27CN¥35.183
Jun ’24CN¥64.00
CN¥79.37
+24.0%
3.3%CN¥82.67CN¥76.27CN¥39.183
May ’24CN¥68.61
CN¥77.73
+13.3%
1.9%CN¥79.19CN¥76.27CN¥38.632
Dec ’23CN¥76.47
CN¥115.11
+50.5%
7.1%CN¥123.32CN¥106.90CN¥66.802
Nov ’23CN¥73.80
CN¥115.11
+56.0%
7.1%CN¥123.32CN¥106.90CN¥64.742

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

China Resources Double-Crane PharmaceuticalLtd

CN¥21.4b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥20.80

7D

-3.9%

1Y

12.1%

Jiangsu Kanion PharmaceuticalLtd

CN¥8.1b

Researches and develops, produces, and sells Chinese medicines.

600557

CN¥14.29

7D

-4.2%

1Y

-23.6%

Dong-E-E-JiaoLtd

CN¥36.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥56.60

7D

-3.0%

1Y

13.2%